Clinical trials: Stereotactic Radiotherapy
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Lung Cancer, Oligometastatic Lung Tumor
One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors
Stereotactic body radiotherapy (SBRT) has become a standard of care for medically inoperable or high-risk operable early-stage non-small cell lung cancer (NSCLC) patients.
- Trial name
- ONE STOP (NCT06236516)
- Testing
- One fraction stereotactic body radiotherapy, HyperSight, Ethos
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Brain Metastases
A Proof-of-principle Study of HBO-SRS for Brain Metastases
Patients with brain metastases who are candidates for treatment with stereotactic radiosurgery (SRS) are potential study participants.
- Trial name
- NCT01850563
- Testing
- Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Prostate Cancer, Prostate Adenocarcinoma
Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)
This study will investigate the safety, tolerability, and effectiveness of giving a higher dose to the part of the prostate which contains the cancer while giving a standard radiation dose to the entire prostate.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01856855
- Testing
- Stereotactic Body Radiation Therapy with Integrated Boost
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- John Fiveash, MD
Large Brain Mets
Fractionated Stereotactic Radiosurgery for Large Brain Metastases
This is a research trial that seeks to break up the total radiation dose into multiple smaller radiation treatments, termed fractionated stereotactic radiosurgery (FSRS) which may make the treatment feasible.
- Trial name
- NCT02054689
- Testing
- Fractionated Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Steven Burton
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
Oligometastases
Stereotactic Body Radiation With Nelfinavir for Oligometastases
Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered.
- Trial name
- NCT01728779
- Testing
- Nelfinavir, Stereotactic Body Radiation (SBRT)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma (HCC)
Y90 Radiation Segmentectomy vs SBRT for HCC
The proposed study is a single site, prospective, randomized pilot study to assess the feasibility of recruitment of patients into a trial evaluating the efficacy and tolerability of selective transarterial Y90 radioembolization…
- Trial name
- SBRT vs Y90 (NCT04235660)
- Testing
- Yttrium-90 Radiation Segmentectomy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Indiana University
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00983359
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Brain Neoplasms, Adult, Malignant
Stereotactic Radiosurgery (SRS) Dose-Escalation Study for Brain Metastasis
SRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses.
- Trial name
- SRS (NCT02645487)
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Oligometastatic Renal Cell Carcinoma
SAbR For Oligometastatic Renal Cell Carcinoma
Hypothesis: Stereotactic ablative body radiation (SAbR) prolongs progression-free survival for patients with oligometastatic kidney cancer (RCC) and delays the initiation of systemic therapy.
- Trial name
- NCT02956798
- Testing
- Stereotactic ablative body radiation (SABR)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Texas Southwestern Medical Center
Melanoma, Metastatic Malignant Neoplasm in the Spine
Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery
This pilot clinical trial studies adaptive staged stereotactic body radiation therapy (SBRT) in treating patients with spinal metastases that cannot be removed by surgery.
- Conditions
- Melanoma, Metastatic Malignant Neoplasm in the Spine, Renal Cell Carcinoma, Soft Tissue Sarcoma
- Trial name
- NCT02527304
- Testing
- Image-Guided Adaptive Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Albert Einstein College of Medicine
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic body radiation therapy may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00087438
- Testing
- stereotactic body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Radiation Therapy Oncology Group
Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
Nivolumab (brand name Opdivo): IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity; SABR, dose…
- Trial name
- NCT02781506
- Testing
- Nivolumab, SAbR
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Sarcoma, Metastatic Disease
Stereotactic Radiation Therapy for Pediatric Sarcomas
The stereotactic body radiation therapy (SBRT) literature focuses on clinical outcomes in the adult population. However, SBRT has a particularly strong rationale for application in pediatrics given that high biologically…
- Conditions
- Sarcoma, Metastatic Disease, Bony Sites
- Trial name
- NCT01763970
- Testing
- SBRT
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with…
- Trial name
- STOMP (NCT03004183)
- Testing
- ADV/HSV-tk, Valacyclovir, SBRT
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma
- Trial name
- NCT02858869
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue near the tumor.
- Trial name
- NCT00551369
- Testing
- SBRT
- Where
- 19 sites in United States
- Volunteers
- 33 people
- Sponsor
- Radiation Therapy Oncology Group
Non-Small Cell Lung Cancer
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected Stage I or II (Stage IIB N0, M0)…
- Trial name
- NCT03924869
- Testing
- Stereotactic Body Radiotherapy (SBRT), Pembrolizumab
- Where
- 194 sites in United States, Argentina and 22 more
- Volunteers
- 448 people
- Sponsor
- Merck Sharp & Dohme LLC